Acta Scientific Pharmacology

Review Article Volume 1 Issue 12

Kidney Stone Disease: A Brief Review

Vidyashree B*, Karunakar Hegde and AR Shabaraya

Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka, India

*Corresponding Author: Vidyashree B, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka, India.

Received: June 20, 2020; Published: January 30, 2020



  Kidney stone disease is the crystal formation within the kidneys. It’s affecting about 12% of the population. It is associated with increased risk of the renal–failure. The most common type of stone formation is calcium oxalate formed at Randall’s plaque on the renal papillary surfaces. The mechanism of stone formation involves nucleation, crystal growth, aggregation, and retention of urinary stone constituents within the kidney. An imbalance between factors that encourage or inhibit urinary crystallization modulates these steps.

Keywords: Kidney Stone; Calcium Oxalate



  1. Khan SR., et al. “Kidney stones”. Nature Reviews Disease Primers 2 (2016): 16008.
  2. Teichman JM. “Acute renal colic from ureteral calculus”. New England Journal of Medicine7 (2004): 684-693.
  3. Moe OW. “Kidney stones: pathophysiology and medical management”. The Lancet9507 (2006): 333-344.
  4. Romero V., et al. “Kidney stones: a global picture of prevalence, incidence, and associated risk factors”. Reviews in Urology 12 (2010): e86.
  5. Alelign T and Petros B. “Kidney stone disease: an update on current concepts”. Advances in Urology (2018).
  6. Chaudhary A., et al. “In vitro evaluation of Terminalia arjuna on calcium phosphate and calcium oxalate crystallization”. Indian Journal of Pharmaceutical Sciences3 (2010): 340.
  7. Evan AP., et al. “Mechanisms of human kidney stone formation”. Urolithiasis1 (2015): 19-32.
  8. Evan AP., et al. “Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle”. The Journal of Clinical Investigation5 (2006): 607-616.
  9. Kok DJ and Khan SR. “Calcium oxalate nephrolithiasis, a free or fixed particle disease”. Kidney International3 (1994): 847-854.
  10. Khan SR and Hackett RL. “Role of organic matrix in urinary stone formation: an ultrastructural study of crystal matrix interface of calcium oxalate monohydrate stones”. Journal of Urology 150 (1993): 239-245.
  11. Tsujihata M. “Mechanism of calcium oxalate renal stone formation and renal tubular cell injury”. International Journal of Urology2 (2008): 115-120.
  12. Khan SR., et al. “Presence of lipids in urine, crystals and stones: implications for the formation of kidney stone”. Kidney International6 (2002): 2062-2072.
  13. Aggarwal KP., et al. “Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulator”. BioMed Research International (2013).
  14. Fasano JM and Khan SR. “Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: an in vitro study”. Kidney International1 (2001): 169-178.
  15. Evan AP., et al. “Mechanism of formation of human calcium oxalate renal stones on Randall's plaque, The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology”. Advances in Integrative Anatomy and Evolutionary Biology10 (2007): 1315-1323.
  16. Khan SR and Kok DJ. “Modulators of urinary stone formation”. Frontiers in Bioscience 629 (2004): 1450-1482.
  17. Basavaraj DR., et al. “The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones”. EAU-EBU Update Series3 (2007): 126-136.
  18. Park S and Pearle MS. “Pathophysiology and management of calcium stones”. Urologic Clinics of North America 3 (2007): 323-334.
  19. KOHLSTADT I and FRASSETTO L. “Treatment and Prevention of Kidney Stones: An Update”. American Family Physician 11 (2011).


Citation: Vidyashree B. “Kidney Stone Disease: A Brief Review".Acta Scientific Pharmacology 2.2 (2021): 17-21.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

Contact US